Availability of clinical genomic sequencing tests globally: whole-exome sequencing, non-invasive prenatal testing and tumour sequencing
| Test | North America | Central/ South America | Europe | Middle east | Asia/Oceania | Other countries |
| Whole-exome sequencing | USA Canada Mexico | Brazil Argentina Colombia Argentina Peru | UK, Germany Belgium, Denmark, Netherlands, Sweden, Italy, Spain, Ireland, Estonia, Finland, France | Saudi Arabia Qatar Turkey Israel | Australia China Japan South Korea Taiwan | South Africa |
| Non-invasive prenatal testing | USA Canada Mexico | Brazil Argentina Colombia Argentina Peru | UK, France, Belgium, Denmark, Netherlands, Switzerland, Czech Republic, Sweden, Germany, Italy, Spain Ireland | Saudi Arabia Qatar Turkey Israel | Australia China Japan South Korea Taiwan | South Africa |
| Tumour sequencing | USA Canada Mexico | Brazil Argentina Chile Colombia Venezuela Peru | UK, Belgium, Czech Republic, Netherlands, Sweden, Norway, France, Germany, Spain, Italy, Estonia, Finland, Ireland | Saudi Arabia Qatar Turkey Israel | Australia China Japan South Korea Taiwan | South Africa Egypt |
Availability is based on the best available information obtained using a range of sources, including the grey literature and interviews with experts (personal communications, Veronique Forest, Marius Van Den Berg, 10/20/20).30 However, this table is illustrative and thus may not include all relevant countries. Also, we could not assess the availability of whole genome (vs exome) independently but many countries have both tests available.